InterMune has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its pirfenidone, an investigational treatment for adult patients with idiopathic pulmonary fibrosis (IPF).
The company had submitted a new drug application to the FDA in May for pirfenidone and noted a target FDA review of six months under the Prescription Drug User Fee Act.
InterMune chairman, president and CEO Dan Welch said: "The breakthrough therapy designation underscores the significant need to help patients with this irreversible and ultimately fatal disease, particularly as no FDA-approved therapies are currently available.
"We are pleased that the FDA recognised the importance of pirfenidone as a potential new therapy for IPF, a disease with great unmet medical need."
An anti-fibrotic agent, pirfenidone inhibits the synthesis of TGF-beta and plays a key role in fibrosis. The drug also inhibits the synthesis of TNF-alpha, a cytokine that is known to have an active role in inflammation.
InterMune received marketing approval from the European Commission for Esbriet (pirfenidone) in February 2011 for treatment of adults with mild to moderate IPF. This approval authorised marketing of Esbriet in all 28 EU member states.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataHealth Canada has approved Esbriet in October 2012 and the company launched the IPF drug in January 2013.
Under different trade names, pirfenidone is also approved in China, India, Japan, South Korea, Argentina and Mexico. It is not approved for sale in the US.
